ARS Pharmaceuticals, Inc. Capital Expenditures
ARS Pharmaceuticals, Inc. (SPRY) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $197.00K, a 40.71% increase year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $339.00K, a 39.79% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $563.00K, a 221.71% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $175.00K, a 12.06% decline from fiscal 2022.
- ARS Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $199.00K, a 261.82% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $197.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $197.00K derived: sum of 3 quarters · filed 2026-05-15 | $248.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $197.00K derived: sum of 2 quarters · filed 2026-03-09 | $248.00K derived: sum of 3 quarters · filed 2026-08-13 | $339.00K 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $248.00K derived: sum of 2 quarters · filed 2026-08-13 | $339.00K 10-Q · filed 2025-11-10 | $641.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $142.00K 10-Q · filed 2026-08-13 | $444.00K derived: sum of 3 quarters · filed 2026-08-13 | $584.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $91.00K 10-Q · filed 2026-05-15 | $393.00K derived: sum of 2 quarters · filed 2026-05-15 | $533.00K derived: sum of 3 quarters · filed 2026-05-15 | $571.00K derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $442.00K derived: sum of 2 quarters · filed 2026-03-09 | $480.00K derived: sum of 3 quarters · filed 2026-03-09 | $563.00K 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $178.00K derived: sum of 2 quarters · filed 2025-11-10 | $261.00K 10-Q · filed 2025-11-10 | $170.00K derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $121.00K 10-Q · filed 2025-08-13 | $30.00K derived: sum of 3 quarters · filed 2025-08-13 | $73.00K derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $83.00K 10-Q · filed 2025-05-14 | -$8.00K derived: sum of 2 quarters · filed 2025-05-14 | $35.00K derived: sum of 3 quarters · filed 2025-05-14 | $65.00K derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$48.00K derived: sum of 2 quarters · filed 2025-03-20 | -$18.00K derived: sum of 3 quarters · filed 2025-03-20 | $175.00K 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $73.00K derived: sum of 2 quarters · filed 2024-11-13 | $266.00K 10-Q · filed 2024-11-13 | $392.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $223.00K 10-Q · filed 2024-08-06 | $349.00K derived: sum of 3 quarters · filed 2024-08-06 | $379.00K derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $193.00K 10-Q · filed 2024-05-09 | $319.00K derived: sum of 2 quarters · filed 2024-05-09 | $349.00K derived: sum of 3 quarters · filed 2024-05-09 | $371.00K derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $156.00K derived: sum of 2 quarters · filed 2024-03-21 | $178.00K derived: sum of 3 quarters · filed 2024-03-21 | $199.00K 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $52.00K derived: sum of 2 quarters · filed 2023-11-09 | $73.00K 10-Q · filed 2023-11-09 | $684.00K 10-Q · filed 2022-11-02 | -$694.00K derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $43.00K 10-Q · filed 2023-08-10 | $618.00K 10-Q · filed 2022-08-11 | -$724.00K derived: sum of 3 quarters · filed 2023-08-10 | -$637.00K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $21.00K 10-Q · filed 2023-05-15 | $332.00K 10-Q · filed 2022-05-12 | -$746.00K derived: sum of 2 quarters · filed 2023-05-15 | -$659.00K derived: sum of 3 quarters · filed 2023-05-15 | $41.00K derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$767.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$680.00K derived: sum of 2 quarters · filed 2023-03-23 | $20.00K derived: sum of 3 quarters · filed 2023-03-23 | $55.00K 10-K · filed 2023-03-23 | $1.37M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $787.00K derived: sum of 2 quarters · filed 2022-11-02 | $822.00K 10-Q · filed 2022-11-02 | $1.07M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $735.00K 10-Q · filed 2022-08-11 | $982.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.61M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $35.00K 10-Q · filed 2022-05-12 | $282.00K derived: sum of 2 quarters · filed 2022-05-12 | $914.00K derived: sum of 3 quarters · filed 2022-05-12 | $919.00K derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $879.00K derived: sum of 2 quarters · filed 2022-03-31 | $884.00K derived: sum of 3 quarters · filed 2022-03-31 | $917.00K 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $632.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $637.00K derived: sum of 2 quarters · filed 2021-11-10 | $670.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $38.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $33.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |